Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
YM155
|
| gptkbp:CASNumber |
356068-94-5
|
| gptkbp:chemicalFormula |
C20H19BrN4O3
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| https://www.w3.org/2000/01/rdf-schema#label |
NSC 339555
|
| gptkbp:is_investigated_for |
treatment of cancer
|
| gptkbp:IUPACName |
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-2-ium bromide
|
| gptkbp:mechanismOfAction |
survivin suppressant
|
| gptkbp:molecularWeight |
443.3 g/mol
|
| gptkbp:PubChem_CID |
11364422
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
survivin
|
| gptkbp:usedFor |
anticancer agent
|
| gptkbp:was_developed_by |
gptkb:Astellas_Pharma
|
| gptkbp:bfsParent |
gptkb:bryostatin-1
|
| gptkbp:bfsLayer |
7
|